Other News To Note
Tuesday, February 12, 2013
AMRI, of Albany, N.Y., signed a license agreement with Chai Therapeutics LLC, an affiliate of Bessor Pharma LLC, of Framingham, Mass., to develop its tubulin inhibitor, ALB109564, which is in Phase I testing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.